"Effect of Screening Using Imaging (CT/ EUS) on Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) in Patients With New Onset Diabetes (NOD)" - A Prospective Pilot Observational Study
Not yet recruiting
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Registration Number
- NCT06044064
- Lead Sponsor
- Asian Institute of Gastroenterology, India
- Brief Summary
To assess whether EUS (Endoscopic Ultrasound) can serve as a valuable diagnostic tool for identifying PDAC at an early stage in individuals who have recently been diagnosed with diabetes.
Purpose: To improve the rates of early detection of pancreatic cancer.
Pancreatic ductal adenocarcinoma (PDAC) is a type of cancer that starts in the pancreas, a gland located in your abdomen. It happens when some cells in the pancreas start growing abnormally and form a cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Age > 50 years
- Patients diagnosed with diabetes based on FBS/ PPBS/ HbA1C
- Presence of atleast 1 FBS parameter measured in the past 6-18 months which was not > 125 mg/dl
- END-PDAC score > 2
Exclusion Criteria
- Known or newly detected chronic pancreatitis
- Past history of pancreatic cancer
- History of steroid use
- Contraindications for EUS
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of PDAC at 3 years 3yrs
- Secondary Outcome Measures
Name Time Method • Incidence of PDAC at baseline • Incidence of resectable PDAC at baseline • Incidence of resectable PDAC at 3 years baseline and 3yrs